Disclosures for "Real-world Analysis of the Clinical Care Pathway of Patients Living with Alzheimer’s Disease in the United States According to Stage of Cognitive Impairment at Diagnosis"
-
Dr. Lv has received personal compensation for serving as an employee of Novo Nordisk .
-
Ms. Fazio-Eynullayeva has received personal compensation for serving as an employee of Novo Nordisk. Ms. Fazio-Eynullayeva has stock in Novo Nordisk.
-
Dr. Mystkowski has received personal compensation for serving as an employee of Novo Nordisk. Dr. Mystkowski has stock in Novo Nordisk.
-
Sarah Cotton has nothing to disclose.
-
Eddie Jones, BA has nothing to disclose.
-
Ms. Kirkman has nothing to disclose.
-
Dr. Mattke has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eisai. Dr. Mattke has received personal compensation in the range of $500-$4,999 for serving as a Consultant for C2N. Dr. Mattke has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novo Nordisk. Dr. Mattke has received personal compensation in the range of $0-$499 for serving as an officer or member of the Board of Directors for Senscio Systems. The institution of Dr. Mattke has received research support from various companies, CMS.